Chronic Rhinosinusitis with Nasal Polyposis: Emerging Data and New Insights for Treatment

Program Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negative impact on patient quality of life. Recent developments have uncovered numerous potential treatment approaches for CRSwNP by targeting type 2 inflammatory pathways; however, only patients expressing these immune phenomena will respond to these novel treatment approaches. This interactive infographic will cover the diagnosis, pathophysiology, and new/emerging treatment strategies for CRSwNP, including demonstrative case challenges, questions, audio narration, and interactive educational diagrams.

Credit Expired
CE Credit Expired
Expires: June 9, 2021

Target Audience

The target audience for this activity is allergy-immunology, ENT, and pulmonology clinicians (MD/DO/NP/PA) managing patients with CRSwNP.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Accurately diagnose patients with Th2-driven nasal polyps (chronic rhinosinusitis with nasal polyps [CRSwNP]) who may be eligible for treatment with biologic therapy
  • Describe the underlying pathophysiology of rhinosinusitis-associated nasal polyps and how this may be used to guide selection of novel biologic therapy
  • Evaluate emerging agents for CRSwNP based on their efficacy and safety data

Activity Faculty


Bradley E. Chipps, MD

Medical Director, Respiratory Therapy
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources